Edition:
United Kingdom

Xenetic Biosciences Inc (XBIO.OQ)

XBIO.OQ on NASDAQ Stock Exchange Capital Market

2.07USD
12 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.07
Open
$2.05
Day's High
$2.08
Day's Low
$2.05
Volume
328
Avg. Vol
4,676
52-wk High
$5.90
52-wk Low
$1.75

Summary

Name Age Since Current Position

Jeffrey Eisenberg

51 2017 Chief Executive Officer, Chief Operating Officer, Director

James Parslow

52 2017 Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

Curtis Lockshin

2017 Chief Scientific Officer

Colin Hill

69 2017 Treasurer, Secretary, Director

Timothy Cote

54 2014 Director

Firdaus Dastoor

62 2014 Director

Artur Isaev

47 2014 Director

Roman Knyazev

35 2014 Director

Roger Kornberg

69 2016 Director

James Callaway

2017 Independent Director

Dmitry Genkin

49 2017 Independent Director

Adam Logal

2017 Independent Director

Biographies

Name Description

Jeffrey Eisenberg

Mr. Jeffrey F. Eisenberg is Chief Executive Officer, Chief Operating Officer, Director of the Company. From 1998 to 2016, Mr. Eisenberg worked at Noven Pharmaceuticals, Inc., a Miami, Florida based subsidiary of Hisamitsu Pharmaceutical, Inc. Most recently, from 2009-2016, Mr. Eisenberg worked as Noven’s President, CEO and as a member of its board of directors. In addition to being a member of our board of directors, currently, Mr. Eisenberg is a member of the board of directors of Mabvax Therapeutics, Inc., a San Diego, California based publicly traded clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer. Mr. Eisenberg obtained his Juris Doctor at Columbia University Law School, New York, NY, and a Bachelor of Science in Economics from the Wharton School, University of Pennsylvania, Philadelphia, PA.

James Parslow

Mr. James F. Parslow has been appointed as Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer of the Company., effective April 24, 2017. Mr. Parslow, has served as the Company’s Chief Financial Officer since April 3, 2017. Prior to joining the Company, he served as Chief Financial Officer, Treasurer and Secretary of World Energy Solutions, Inc., a publicly-traded business-to-business e-commerce company brokering energy and environmental commodities, from 2006 until its acquisition by EnerNOC, Inc. in 2015. From 2015 until April 2017, he served as an independent consultant providing interim chief financial officer services to multiple emerging technology companies. Mr. Parslow is a Certified Public Accountant with more than 25 years of experience serving private and public companies in the alternative energy, online auction, and high-tech manufacturing industries. He holds an A.B. in Economics and Accounting from the College of the Holy Cross and an M.B.A. with a concentration in Finance from Bentley University.

Curtis Lockshin

Dr. Curtis A. Lockshin serves as Chief Scientific Officer of the Company. Dr. Lockshin is a Ph.D. in Biological Chemistry (Massachusetts Institute of Technology 1998), who has held management positions in development and commercial stage biotechnology companies, with experience including discovery, preclinical and clinical development, as well as commercial manufacturing. Over the past five years, Dr. Lockshin has worked as an officer or consultant of several biotechnology companies, including: (a) from March 2014 to December 2016 as the Vice President of Research & Operations of our company; (b) since May 2013 as President and CEO of Guardum Pharmaceuticals LLC; (c) from September 2014 to December 2016 as an officer of a series of related companies following multiple mergers beginning as CEO of SciVac Ltd (Sept 2014-July 2015), CEO of SciVac Therapeutics Inc. (July 2015-May 2016), and CTO of VBI Vaccines Inc. (May 2016- December 2016); (d) from October 2011 to February 2013 as Vice President of Corporate R&D Initiatives for OPKO Health. Dr. Lockshin is also a member of the board of directors of RXi Pharmaceuticals (RXII) (Since April 2013), and has been a director of Chromadex Inc (CDXC) (March 2011 - December 2013) and Sorrento Therapeutics (SRNE) (October 2009 – September 2012).

Colin Hill

Mr. Colin William Hill is Treasurer, Secretary, Director of the Company. Mr. Hill was appointed Chief Financial Officer at Xenetic UK in June 2007. Prior to joining Xenetic he was Finance Director (2001-2003) and non-executive Chairman (2003) at Greenchip Investments plc. Mr Hill has been a member of the Chartered Institute of Management Accountants since 1968 and spent 15 years in industry specialising in corporate turnaround and development work before becoming a freelance consultant in 1981. Since that time, he has focused on due diligence relating to corporate finance assignments in small and medium enterprises and public companies with small market capitalizations in the UK, USA, and overseas. Between 1998 and 2008 Mr Hill was Group Finance Director of Arlington Group plc, a company listed on AIM.

Timothy Cote

Dr. Timothy R. Cote, M.D., MPH, is Director of the Company. Dr. Cote has had an extensive and successful career in the public health service with both government departments and patient advocacy groups. Dr. Cote most recently served as the Chief Medical Officer for the National Organization for Rare Disorders (NORD). Dr. Cote served for four years as the Director of the U.S. FDA Office of Orphan Products Development, where he oversaw a staff of 45 physicians, pharmacists and other professionals and a budget of $17 million in implementation of the U.S. Orphan Drug Act. Before joining the FDA, Dr. Cote was affiliated with the Centers for Disease Control and Prevention (CDC), serving as Country Director for Rwanda. He has also served as Senior Federal Advisor to the Director, District of Columbia Department of Health; Branch Chief, Therapeutics and Blood Safety, FDA Center for Biologics Evaluation and Research (CBER); and Medical Director, Cancer Statistics Branch, National Cancer Institute. In addition, Dr. Cote is Professor of Regulatory Practice at the Keek Graduate Institute teaching modules covering both U.S. and European regulatory affairs. Dr. Cote holds a B.A. from Syracuse University, MPH from Harvard School of Public Health, and MD from Howard University College of Medicine.

Firdaus Dastoor

Mr. Firdaus Jal Dastoor is Director of the Company. Mr. Dastoor was appointed non-executive Director of Xenetic UK in July 2007. He has been a Fellow Member of The Institute of Company Secretaries of India since 2008 and began his career as a company secretary. He was Company Secretary of the Poonawalla Group until 1994. He then took on assignments involved in business development strategies and operations. Mr. Dastoor is on the board of several companies operating in the field of engineering products, life sciences and biotech, international trade, financial services and quality standards certifications. Currently, he is a Group Director of the Poonawalla Group of Companies in charge of Finance and Corporate Affairs. Based on Mr. Dastoor’s experience in the field of life sciences and biotechnology, finance and business development, the Board believes Mr. Dastoor has the appropriate set of skills to serve as a member of our Board.

Artur Isaev

Mr. Artur Isaev is Director of the Company. Mr. Isaev is a General Director and a majority shareholder of Human Stem Cells Institute OJSC, Russia’s public biotech company, headquartered in Moscow. Mr. Isaev has a degree in Medicine and MBA. He started his business career as a top manager in a brokerage, investment and auditing companies. In 2003 he founded Human Stem Cells Institute and from the very beginning has occupied the post of its General Director. Mr. Isaev is a vice-president of a nongovernmental Organization of Experts in Cell Technologies and Regenerative Medicine. Based on Mr. Isaev’s medical education and his experience in clinical stage biotechnology companies, the Board believes Mr. Isaev has the appropriate set of skills to serve as a member of our Board.

Roman Knyazev

Mr. Roman Knyazev is Director of the Company. Roman Knyazev has been a Senior Investment Manager for Rusnano Moscow since 2009 and is currently on the board of several biotechnology companies. In his current role, he provides technical expertise, asset valuation, financial modelling and business valuation as well as develops and presents investment strategies and project financing to clients. In 2003, he began his career as Chief Financial Officer of Biotec Pharma Moscow where he gained experience in both the financial and management sector. Mr. Knyazev led the development and implementation of management accounting and budgeting processes as well facilitated internal audits of regional branches. From 2005 to 2007 he was a Senior Associate with Deloitte & Touche in Moscow where he organized and co-managed client training conferences, participated in client negotiations, reengineered existing business processes, participated in setting up a client accounting management system and carried out value-based management projects. He is Director of the Company.

Roger Kornberg

Prof. Dr. Roger D. Kornberg Ph.D., is Director of the Company. Dr. Kornberg is an American biochemist and professor of structural biology at Stanford University School of Medicine. Dr. Kornberg was awarded the Nobel Prize in Chemistry in 2006 for his studies of the molecular basis of eukaryotic transcription. Dr. Kornberg became a postdoctoral research fellow at the Laboratory of Molecular Biology in Cambridge, England and then an Assistant Professor of Biological Chemistry at Harvard Medical School in 1976, before moving to his present position as Professor of Structural Biology at Stanford Medical School in 1978. He earned his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. Dr. Kornberg has served on the Scientific Advisory Boards of the following companies: Cocrystal Discovery, Inc. (Chairman), ChromaDex Corporation (Chairman), StemRad, Ltd, Oplon Ltd (Chairman), and Pacific Biosciences. He has also been a director for the following companies: OphthaliX Inc., Protalix BioTherapeutics, Can-Fite BioPharma, Ltd and Teva Pharmaceutical Industries, Ltd.

James Callaway

Mr. James Eric Callaway, Ph.D., is Independent Director of the company. He joins the Xenetic Board of Directors with over 30 years of experience in the execution of product development operations for biotherapeutics. Dr. Callaway has an established track record of achievement against challenging technologies and aggressive project timelines. He currently serves as a Corporate Strategy Consultant at Callaway Innovations. Dr. Callaway is a seasoned CEO within the venture-backed biotech community and over the course of his career he has built and operated two companies, transforming each from research companies to clinical stage operating entities. Prior to these efforts, Dr. Callaway held multiple senior leadership positions at Elan Pharmaceuticals, including simultaneously acting as Head of Development and overseeing the complex partnership with Wyeth Pharmaceuticals in the Alzheimer’s disease immunotherapy program. He has developed antibodies for a wide-range of therapeutic applications over the past two decades, including treatments of multiple sclerosis (Tysabri®: pharmaceutical development), Alzheimer’s disease (bapineuzumab: Program Executive), and blood-brain barrier transport, and has worked with the United Stated Food and Drug Administration on multiple orphan drug development programs.

Dmitry Genkin

Dr. Dmitry Dmitrievich Genkin was Director of the Company. He was previously a party to a consulting agreement with the Company that was mutually terminated on August 1, 2017, pursuant to which he was paid approximately $190,000 from January 1, 2016 through August 1, 2017. Pursuant to the consulting agreement, Dr. Genkin provided advisory services related to the Company’s XBIO-101 and Oncohist programs. Dr. Genkin also previously served as a member of the Board until May 3, 2016, and the Company paid Dr. Genkin $1,074 for his services as a director during 2016.

Adam Logal

Mr. Adam Logal is Independent Director of the company. He joins the Xenetic Board of Directors with over 15 years of experience in the biopharmaceuticals industry. Since April 2014, Mr. Logal has served as Senior Vice President, Chief Financial Officer, Chief Accounting Officer and Treasurer of OPKO Health, Inc. and from March 2007 until April 2014 served as OPKO’s Vice President of Finance, Chief Accounting Officer and Treasurer. Mr. Logal is a director of VBI Vaccines, Inc. and serves as its Audit Committee Chairman. Prior to joining OPKO, Mr. Logal served in various financial management roles at Nabi Biopharmaceuticals, a commercial stage biopharmaceutical company. Mr. Logal is a strategic finance executive with extensive experience in SEC compliance and reporting, domestic and international finance, strategic planning, cash flow management, budgeting, taxation, treasury and business development.